UPDATE – Ocuphire Pharma initiates VEGA-3 Phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia Page 1

Topline data from VEGA-3 Phase 3 study expected in first half of 2025

Topline data from the LYNX-2 Phase 3 study in patients with reduced low-light visual acuity following keratorefractive surgery are expected in the first quarter of 2025

FARMINGTON HILLS, Mich., Sept. 5, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on the development and commercialization of small molecule therapies for the treatment of patients with retinal and refractive errors of the eye, today announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants.